Edgestream Partners L.P. Sells 69,781 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Edgestream Partners L.P. trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 81.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,220 shares of the biopharmaceutical company's stock after selling 69,781 shares during the quarter. Edgestream Partners L.P.'s holdings in Halozyme Therapeutics were worth $775,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock worth $175,194,000 after acquiring an additional 30,901 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Halozyme Therapeutics by 0.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after purchasing an additional 9,780 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Halozyme Therapeutics by 28.0% in the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after purchasing an additional 191,465 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 60.0% in the fourth quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company's stock valued at $31,112,000 after purchasing an additional 243,940 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of Halozyme Therapeutics by 6.2% in the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company's stock valued at $31,204,000 after purchasing an additional 31,871 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Remove Ads

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $61.45 on Wednesday. The firm's fifty day moving average price is $55.96 and its two-hundred day moving average price is $54.68. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53. The firm has a market capitalization of $7.57 billion, a P/E ratio of 17.92, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 31,697 shares of company stock worth $1,754,451. 2.40% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.